Pembrolizumab autoimmune related diabetes:Moving forward,keep learning  

作　　者：Jose Angel Garcia Diego Alcaraz Esther Holgado Felipe Couñago 

机构地区：[1]Department of Medical Oncology,GenesisCare Spain-San Francisco de Asis University Hospital,Madrid 28002,Spain [2]Department of Chief of Medical Oncology,GenesisCare Spain-San Francisco de Asis University Hospital,Madrid 28002,Spain [3]Department of Chief of Radiation Oncology,GenesisCare-Vithas La Milagrosa Hospital,Madrid 28010,Spain

出　　处：《World Journal of Clinical Oncology》2024年第5期576-579,共4页世界临床肿瘤学杂志（英文版）

摘　　要：Immune checkpoint inhibitors(and more specifically programmed cell death 1/programmed cell death ligand 1 inhibitors as Pembrolizumab)initiated a revolution in the field of melanoma and have now expanded to several tumor subtypes and in increasingly broader clinical contexts,including the adjuvant and neoadjuvant setting,with potentially curable patients and prolonged survival.The side effects related to these drugs include a wide spectrum of manifestations,with endocrinological adverse events being some of the most frequent.Pembrolizumab-induced type 1 diabetes mellitus is an infrequent but potentially serious and not clearly reversible side effect that possesses characteristic clinical features and has high morbidity and mortality,with a chronic impact on quality of life.The etiopathogenesis of this phenomenom needs to be further investigated and a collaborative effort through the involvement of oncologists and other medical specialists is necessary for the correct identification and management of patients at risk.

关 键 词：Immune checkpoints Pembrolizumab IMMUNOTHERAPY Side effects Endocrine system Diabetes mellitus 

分 类 号：R739.5[医药卫生—肿瘤] R758.51[医药卫生—临床医学]